Jack A. Khattar is the Chief Executive Officer, President, and Secretary at Supernus Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. With a robust career spanning several decades in the pharmaceutical industry, Khattar has played a pivotal role in steering Supernus towards significant growth and success. He joined Supernus in 2005 and has been instrumental in leading the company through its transition from a development-stage entity to a fully integrated pharmaceutical company with multiple approved products. Before joining Supernus, Khattar held various leadership positions in the industry, including roles at Shire Pharmaceuticals and Roberts Pharmaceutical Corporation. His extensive experience in drug development, regulatory affairs, and commercialization has been crucial in guiding Supernus' strategic direction. Under his leadership, Supernus has successfully launched several products, including Trokendi XR for epilepsy and migraine prevention, and Oxtellar XR for the treatment of epilepsy. Khattar's vision and dedication to improving patient outcomes have cemented his reputation as a respected leader in the field of neuroscience. As CEO, President, and Secretary, Khattar oversees the overall operations and strategic planning of Supernus Pharmaceuticals. He is committed to fostering innovation and advancing the company's pipeline, which includes promising candidates for the treatment of Parkinson's disease and epilepsy. His leadership has not only driven the company's growth but also its commitment to delivering high-quality, effective treatments to patients worldwide. Khattar's contributions have been recognized within the industry, and his ongoing efforts continue to shape the future of Supernus Pharmaceuticals.